Mylène Jansen

344 Chapter 16 Supplementary Table 1 : Biomarker levels at baseline, 3 weeks and 6 weeks post knee joint distraction Analyte Baseline 3 weeks Effect size P- value 6 weeks Effect size P- value Activin A (ng/ml) 10.5 (8.1–12.9) 4.0 (3.0–5.0) -6.5 0.003 3.7 (2.0–5.4) -6.8 0.0002 LTBP2 (ng/ml) 3.0 (2.7–3.3) 3.1 (2.0–3.2) 0.1 0.37 3.4 (2.5–4.0) 0.4 0.05 TGF β -1 (ng/ml) 0.5 (0.4–1.1) 2.0 (1.1–2.1) 1.5 0.01 2.6 (1.3–5.3) 2.1 0.0003 FGF-2 (pg/ml) 26.6 (13.0–69.3) 39.3 (8.6–77.4) 12.7 0.42 191.3 (38.4–496.1) 164.7 0.01 TIMP-1 (ng/ml) 729.0 (563.1–1163.5) 1118.0 (717.5–1568.0) 389 0.02 844.2 (624.3–1225.0) 115.2 0.11 TSG-6 (ng/ml) 58.5 (28.5–156.9) 122.4 (73.7–227.4) 63.9 0.29 100.0 (42.4–164.3) 41.5 0.21 IL-6 (pg/ml) 11.3 (4.2–28.4) 70.9 (23.2–236.7) 59.6 0.02 67.9 (23.2–366.2) 56.6 0.004 MCP-1 (pg/ml) 410.0 (282.9–482.6) 524.8 (485.5–658.1) 114.8 0.25 565.1 (440.1–681.4) 155.1 0.002 IL-8 (pg/ml) 23.1 (16.0–35.3) 96.6 (28.7–122.6) 73.5 0.01 33.6 (19.8–56.4) 10.5 0.31 MMP3 (ng/ml) 444.3 (215.7–815.0) 912.2 (358.2–1623.3) 467.9 0.86 369.0 (190.9–1361.8) -75.3 0.53 Median and interquartile range are given. Comparison was by Wilcoxon signed rank test, comparing mean of duplicate measures at 3 weeks or 6 weeks to measures at baseline. Data are also shown graphically in Figure 2 (some units are shown in ng/ml rather than pg/ml in this table). Effect size is calculated as the difference of medians. FGF- 2: basic fibroblast growth factor; IL-6: interleukin 6; IL-8: interleukin 8; LTBP2: latent-transforming growth factor beta-binding protein 2; MCP-1: monocyte chemoattractant protein 1; MMP3, matrix metalloproteinase-3; TGF β - 1: transforming growth factor beta 1; TIMP-1: tissue inhibitor of metalloproteinases 1; TSG-6: TNF stimulated protein-6.